On November 18, 2018, the "Expert Seminar on Clinical Positioning of Huperzine A Injection" sponsored by "China Research Hospital" and Wanbangde Pharmaceutical Group Co., Ltd. was held in Beijing. Clinical experts from anesthesiology, critical care medicine, neurology, neurosurgery, etc., as well as well-known pharmacy experts and scholars attended and spoke at the meeting, and conducted in-depth discussions on the clinical positioning of Huperzine A injection. The Chinese Medical Association Anesthesia Experts such as Professor Xiong Lize, the former chairman of the academic committee, expressed their strong interest in this Chinese original drug, and put forward valuable suggestions and guidance for the follow-up research direction of Huperzine A injection.

Former Dean of Xijing Hospital of Fourth Military Medical University, Former Chairman of Anesthesiology Branch of Chinese Medical Association, Professor Xiong Lize, Director of Department of Critical Care Medicine, Chinese People's Liberation Army Air Force General Hospital, Director of Department of Critical Care Medicine, China Association for the Promotion of International Exchanges in Healthcare, Professor Ningbo, Beijing Professor Zhang Tong, Vice President and Director of Neurology Department of Boai Hospital, Professor Zhao Zhigang, Director of the Department of Pharmacy, Beijing Tiantan Hospital Affiliated to Capital Medical University, Professor Ma Jue, Director of the Department of Anesthesiology of Guangdong Provincial People's Hospital, Professor Chang Cheng, Director of the Department of Neurology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Zhejiang Province Professor Zheng Gaoli, Director of Pharmacology Research Office, Institute of Materia Medica, Academy of Medical Sciences, Professor Hu Changping, Deputy Dean of Xiangya School of Pharmacy, Central South University, Professor Zhang Hongfei, Deputy Director of Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Professor Wang Hongwei, Director of Department of Anesthesiology, Zhejiang Tongde Hospital, Zhengzhou More than 20 experts from all over the country, including Professor Fu Xudong, Director of Neurosurgery of the Fifth Affiliated Hospital of the University, Professor Zheng Guoqing, Deputy Director of the Department of Neuropsychiatry, Second Affiliated Hospital of Wenzhou Medical University, Professor Zhang Haiyan, Pharmacology Researcher of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, etc. Scholars attended the seminar.

At the beginning of the meeting, Chairman Zhao Shouming, head of Wanbangde Group Co., Ltd. and Wanbangde Pharmaceutical Group Co., Ltd., delivered a speech, expressing gratitude to the experts and scholars who attended the meeting, and introduced Wanbangde Pharmaceutical and the company's core product Huperzine A injection Liquid and Ginkgo biloba dripping pills, and gave hope on the follow-up research direction pre-achieved by this seminar.

Zhang Haiyan, a researcher from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, made a detailed exposition of the "Research Progress on the Pharmacological and Pharmacological Effects of Huperzine A", and led to the follow-up directions for clinical and pharmaceutical experts to further discuss. Wang Qingqing, project manager of Wanbangde Pharmaceutical Group Co., Ltd., reported on behalf of the company "Huperzine A Injection Product Introduction and Brain Injury Related Research Literature Summary". Combining the two major directions of clinical and pharmacy, the participating experts had a heated discussion on the clinical positioning of Huperzine A injection based on their respective disciplines, and further discussed the decline of postoperative brain cognitive dysfunction (postoperative delirium and The feasibility of carrying out research in the direction of postoperative cognitive dysfunction), sepsis-related encephalopathy, and brain injury.

Huperzine A injection is a natural botanical drug developed by Wanbangde Pharmaceutical (formerly Wenling Pharmaceutical Factory) in cooperation with Shanghai Institute of Materia Medica and Zhejiang Academy of Medical Sciences in 1985. It is one of the few global original drugs in my country. As the original research and production enterprise of this product, Wanbangde Pharmaceutical hopes to sort out suitable clinical positioning through this expert seminar, so as to carry out subsequent post-marketing evaluation and expand new indications.

Wanbangde Pharmaceutical will also accumulate more evidence-based medical evidence that meets the needs of modern medical progress through the development of real-world research and the addition of new indications, and carry forward the scientific research achievements of this Chinese original drug with full intellectual property rights.

The scene of the expert seminar on clinical positioning of Huperzine A injection

The experts listened carefully to the meeting report

Researcher Zhang Haiyan from Shanghai Institute of Materia Medica, Chinese Academy of Sciences made a report on "Research Progress on Pharmacological and Pharmacodynamics of Huperzine A"

Wang Qingqing, project manager of Wanbangde Pharmaceutical Group, made a report on "Huperzine A Injection Product Introduction and Brain Injury Related Research Literature Summary"

Discuss with experts

Discuss with experts

Group photo of participating experts